We are live on ! Find out more
XBIT icon

XBiotech
XBIT

41 hedge funds and large institutions have $9.39M invested in XBiotech in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 19 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.99% less ownership

Funds ownership: 10.05% → 9.06% (-0.99%)

9% less funds holding

Funds holding: 45 → 41 (-4)

15% less capital invested

Capital invested by funds: $11.1M → $9.39M (-$1.69M)

63% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 19

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
41
Holders Change
-4
Holders Change %
-8.89%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
7
Reduced
19
Closed
5
Calls
$7K
Puts
–
Net Calls
+$7K
Net Calls Change
+$7K

Top Buyers

Rank Fund Capital Flow
1
Man Group
Man Group
United Kingdom
+$108K
2
Citadel Advisors
Citadel Advisors
Florida
+$40K
3
Bank of America
Bank of America
North Carolina
+$38.8K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$11.4K
5
BlackRock
BlackRock
New York
+$7.73K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$292K
2
Renaissance Technologies
Renaissance Technologies
New York
-$184K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$113K
4
HF
HRT Financial
New York
-$94.5K
5
RC
RBF Capital
California
-$84K
Name Holding Trade Value Shares
Change 		Change in
Stake
TI
26
Trexquant Investment
Connecticut
$45.6K -$30.7K -8,990 -41%
SF
27
Synovus Financial
Georgia
$41.4K – – –
Citadel Advisors
28
Citadel Advisors
Florida
$41.2K +$40K +11,725 New
Charles Schwab
29
Charles Schwab
California
$36.8K – – –
LFM
30
LGT Fund Management
Liechtenstein
$35.1K – – –
UBS Group
31
UBS Group
Switzerland
$20.7K +$2.09K +614 +12%
Royal Bank of Canada
32
Royal Bank of Canada
Ontario, Canada
$7K – – –
ME
33
McIlrath & Eck
Washington
$2.64K – – –
BNP Paribas Financial Markets
34
BNP Paribas Financial Markets
France
$1.4K -$5.54K -1,626 -80%
TRCT
35
Tower Research Capital (TRC)
New York
$1K -$8.18K -2,400 -93%
FCG
36
Financial Connections Group
California
$1K – – –
IA
37
IFP Advisors
Florida
$1K – – –
Osaic Holdings
38
Osaic Holdings
Arizona
$1K – – –
Wells Fargo
39
Wells Fargo
California
$421 +$10 +3 +3%
Dimensional Fund Advisors
40
Dimensional Fund Advisors
Texas
$290 -$13.2K -3,875 -4%
RC
41
RBF Capital
California
– -$84K -23,172 Closed
Qube Research & Technologies (QRT)
42
Qube Research & Technologies (QRT)
United Kingdom
– -$46K -12,591 Closed
JP Morgan Chase
43
JP Morgan Chase
New York
– -$37.8K -11,098 -100%
Jane Street
44
Jane Street
New York
– -$38K -10,439 Closed
EMG
45
ETF Managers Group
New Jersey
– -$33K -8,982 Closed
CAL
46
Capital Advisors Ltd
Ohio
– -$1K -209 Closed
1
2

XBIT Hedge Fund Activity: Q4 2022 in Review

41 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q4 2022, worth a combined $9.39M — down 15% from $11.1M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of XBIT and 1 opened new positions — a net loss of 4 holders — while 19 trimmed existing stakes and 7 added.

The largest buyer was Man Group, adding an estimated $108K. The largest seller was Millennium Management, cutting an estimated $292K.

  • 41 institutional investors held XBiotech (XBIT) as of Q4 2022, down from 45 in Q3 2022.
  • Funds reported $9.39M of XBiotech stock for Q4 2022, down 15% quarter-over-quarter.
  • 1 fund opened new XBiotech positions in Q4 2022 and 5 closed out, a net change of -4 holders.
  • The largest XBiotech buyer in Q4 2022 was Man Group, an estimated $108K added.
  • The largest XBiotech seller in Q4 2022 was Millennium Management, an estimated $292K sold.

Based on aggregated 13F filings for Q4 2022.